Combination Therapeutic for Long COVID
Long COVID (Post-Acute Sequelae of COVID-19)
Phase 2/3Active (FDA trial accepted Jan 2024, enrollment pending)
Key Facts
Indication
Long COVID (Post-Acute Sequelae of COVID-19)
Phase
Phase 2/3
Status
Active (FDA trial accepted Jan 2024, enrollment pending)
Company
About HealthBio AI
HealthBio AI is a clinical-stage biotech company developing an integrated platform of AI-driven diagnostics and therapeutics for chronic inflammatory diseases. The company's core hypothesis centers on immune dysregulation driven by persistent viral proteins, such as the SARS-CoV-2 S1 protein in Long COVID. With an FDA-accepted Phase 2/3 clinical trial for a Long COVID therapeutic and a commercial diagnostic test, HealthBio AI is pursuing a vertically integrated model from diagnosis to treatment management. The company is privately held and appears to be in an early-revenue stage, supported by diagnostic test sales.
View full company profile